Chinese drugmaker HUYA Bioscience International has entered a strategic partnership agreement with the Tianjin Institute of Pharmaceutical Research (TIPR). HUYA and the TIPR have agreed to promote new drug development in China and worldwide. The agreement offers the first opportunity to HUYA to assess certain research and development projects carried out at the institute and it will provide support and assistance. The agreement allows HUYA to commercialise select programmes from the TIPR in the global market. , HUYA chief technology officer and chief operating officer in China, Clement Gingras, said the partnership would allow HUYA and the TIPR to accelerate innovative drug development in China.